Efficacy and safety of rivaroxaban or fondaparinux thromboprophylaxis in major orthopedic surgery: Findings from the ORTHO-TEP registry

Journal of Thrombosis and Haemostasis

Volumn 10, Issue 10, 2012, Pages 2045-2052

  Beyer Westendorf, J ^a   Lutzner J ^b   Donath, L ^a   Radke, O C ^b   Kuhlisch, E ^c   Hartmann, A ^b   Weiss, N ^a   Werth, S ^a  

^a DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

^b UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

^c DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

Author keywords

Deep vein thrombosis; Fondaparinux; Major orthopedic surgery; Rivaroxaban; Venous thromboembolism; Venous thromboembolism prophylaxis

Indexed keywords

FONDAPARINUX; RIVAROXABAN;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; COXITIS; DEATH; DEEP VEIN THROMBOSIS; DRUG EFFICACY; DRUG SAFETY; ERYTHROCYTE CONCENTRATE; ERYTHROCYTE TRANSFUSION; FEMALE; HEMATOMA; HIP ARTHROPLASTY; HOSPITALIZATION; HUMAN; KNEE ARTHROPLASTY; KNEE SURGERY; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; MULTIPLE ORGAN FAILURE; POSTOPERATIVE HEMORRHAGE; PRIORITY JOURNAL; PROPHYLAXIS; RETROSPECTIVE STUDY; RISK FACTOR; SEPSIS; VENOUS THROMBOEMBOLISM;

ADMINISTRATION, ORAL; AGED; AGED, 80 AND OVER; ANTICOAGULANTS; BLOOD COAGULATION TESTS; DRUG ADMINISTRATION SCHEDULE; FEMALE; GERMANY; HUMANS; KAPLAN-MEIER ESTIMATE; LOGISTIC MODELS; LONGEVITY; MALE; MIDDLE AGED; MORPHOLINES; ORTHOPEDIC PROCEDURES; POLYSACCHARIDES; POSTOPERATIVE HEMORRHAGE; PROPORTIONAL HAZARDS MODELS; REGISTRIES; RETROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; THIOPHENES; TIME FACTORS; TREATMENT OUTCOME; VENOUS THROMBOEMBOLISM;

EID: 84866875400     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/j.1538-7836.2012.04877.x     Document Type: Article

References (19)

1. Nicolaides AN, Breddin HK, Fareed J, Goldhaber S, Haas S, Hull R, Kalodiki E, Myers K, Samama M, Sasahara A. Prevention of venous thromboembolism. International Consensus Statement. Guidelines compiled in accordance with the scientific evidence. Int Angiol 2001; 20: 1-37.
2. Geerts WH, Bergqvist D, Pineo GF, Heit JA, Samama CM, Lassen MR, Colwell CW. Prevention of venous thromboembolism: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008; 133: 381S-453S.
3. Falck-Ytter Y, Francis CW, Johanson NA, Curley C, Dahl OE, Schulman S, Ortel TL, Pauker SG, Colwell CW Jr. Prevention of VTE in Orthopedic Surgery Patients: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141: e278S-325S.
4. Turpie AG, Bauer KA, Eriksson BI, Lassen MR. Fondaparinux vs enoxaparin for the prevention of venous thromboembolism in major orthopedic surgery: a meta-analysis of 4 randomized double-blind studies. Arch Intern Med 2002; 162: 1833-40.
5. Turpie AG, Bauer KA, Eriksson BI, Lassen MR. Superiority of fondaparinux over enoxaparin in preventing venous thromboembolism in major orthopedic surgery using different efficacy end points. Chest 2004; 126: 501-8.
6. Warwick D, Friedman RJ, Agnelli G, Gil-Garay E, Johnson K, FitzGerald G, Turibio FM. Insufficient duration of venous thromboembolism prophylaxis after total hip or knee replacement when compared with the time course of thromboembolic events: findings from the Global Orthopaedic Registry. J Bone Joint Surg Br 2007; 89: 799-807.
7. Wilke T, Moock J, Muller S, Pfannkuche M, Kurth A. Nonadherence in outpatient thrombosis prophylaxis with low molecular weight heparins after major orthopaedic surgery. Clin Orthop Relat Res 2010; 468: 2437-53.
8. Eriksson BI, Kakkar AK, Turpie AG, Gent M, Bandel TJ, Homering M, Misselwitz F, Lassen MR. Oral rivaroxaban for the prevention of symptomatic venous thromboembolism after elective hip and knee replacement. J Bone Joint Surg Br 2009; 91: 636-44.
9. Rothwell PM. External validity of randomised controlled trials: "to whom do the results of this trial apply?" Lancet 2005; 365: 82-93.
10. Fortin M, Dionne J, Pinho G, Gignac J, Almirall J, Lapointe L. Randomized controlled trials: do they have external validity for patients with multiple comorbidities? Ann Fam Med 2006; 4: 104-8.
11. Rosser WW. Application of evidence from randomised controlled trials to general practice. Lancet 1999; 353: 661-4.
12. Donath L, Lutzner J, Werth S, Kuhlisch E, Hartmann A, Gunther KP, Weiss N, Beyer-Westendorf J. Efficacy and safety of venous thromboembolism prophylaxis with fondaparinux or low-molecular weight heparin in a large cohort of consecutive patients undergoing major orthopaedic surgery - findings from the ORTHO-TEP registry. Br J Clin Pharmacol 2012; doi: 10.1111/j.1365-2125.2012.04302.x.
13. Schwarz T, Schmidt B, Schmidt B, Schellong SM. Interobserver agreement of complete compression ultrasound for clinically suspected deep vein thrombosis. Clin Appl Thromb Hemost 2002; 8: 45-9.
14. Schellong SM, Schwarz T, Halbritter K, Beyer J, Siegert G, Oettler W, Schmidt B, Schroeder HE. Complete compression ultrasonography of the leg veins as a single test for the diagnosis of deep vein thrombosis. Thromb Haemost 2003; 89: 228-34.
15. Schulman S, Kearon C. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. J Thromb Haemost 2005; 3: 692-4.
16. Schellong SM. Distal DVT: worth diagnosing? Yes. J Thromb Haemost 2007; 5(Suppl. 1): 51-4.
17. Righini M, Paris S, Le GG, Laroche J, Perrier A, Bounameaux H. Is it worth diagnosing and treating distal deep vein thrombosis? No. J Thromb Haemost 2007; 5: 56-64.
18. Seinturier C, Bosson JL, Colonna M, Imbert B, Carpentier PH. Site and clinical outcome of deep vein thrombosis of the lower limbs: an epidemiological study. J Thromb Haemost 2005; 3: 1362-7.
19. White RH, Henderson MC. Risk factors for venous thromboembolism after total hip and knee replacement surgery. Curr Opin Pulm Med 2002; 8: 365-71.